LifeArc portfolio company RQ Bio’s antibody enters clinical trials

LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…

Evolving our science to solve complex healthcare challenges

Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.

LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis

Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.

LifeArc announces £10m funding call for new chronic respiratory infection therapies

First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge

£100m programme to transform care for people living with chronic lung conditions

More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.

LifeArc responds to the Government’s renewed pledge to increase R&D funding

LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]

LifeArc funds home monitoring trials for people with chronic respiratory conditions

Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.

LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients

Seed funding will be used to scale the solution through the application of machine learning

Call for Government to place medical research at the heart of economic plans

Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…